KPV vs MOTS-c: What's the Difference

KPV and MOTS-c are two research peptides with almost nothing in common beyond sharing a catalogue: KPV is a tripeptide derived from alpha-MSH that the literature studies for its interaction with the NF-κB pathway in inflammation models, while MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, studied for its role in AMPK activation and metabolic regulation. They are not interchangeable and do not belong to the same structural family. They get compared because they sit next to each other in the same research catalogue, not because they investigate the same thing.

Direct comparison

What KPV is and what the literature investigates about it

KPV is one of the smallest research peptides in the catalogue: three amino acids, Lysine-Proline-Valine, corresponding to the C-terminal end of alpha-MSH (alpha-melanocyte-stimulating hormone). That origin is the key to understanding it: it is not a "designed" peptide, it is a fragment of a molecule the body already produces on its own.

The literature on KPV concentrates on two lines of research. One studies its interaction with melanocortin receptors, the same receptors activated by full-length alpha-MSH. The other, more frequently cited in preclinical studies, investigates a receptor-independent mechanism: the effect of KPV on the NF-κB pathway, a central regulator of the cellular inflammatory response. The most commonly used models are intestinal inflammation models, where researchers evaluate how the peptide modulates the expression of pro-inflammatory cytokines in colon tissue.

It is worth reading those studies for what they are: research in cell and animal models, not evidence of an effect in people. The KPV listing in the catalogue is classified as research material, not as a clinical-use input.

What MOTS-c is and why its mechanism is so different

MOTS-c belongs to a family discovered much more recently: mitochondrial-derived peptides (MDPs). Unlike most research peptides, which are encoded in nuclear DNA, MOTS-c is encoded in a region of mitochondrial DNA, within the 12S rRNA gene. It is a 16-amino-acid chain, more than five times longer than KPV.

The mechanism the literature investigates for MOTS-c is metabolic: researchers study its capacity to activate AMPK, a protein kinase that functions as the cell's energy sensor and regulates how the cell uses glucose and fatty acids. The most-cited preclinical models evaluate insulin resistance, diet-induced metabolic stress, and markers of cellular aging. This is a completely separate line of research from KPV's: there is no overlap in receptor, pathway, or experimental model between the two peptides.

The purity report published for this peptide — task 136923 from Janoshik Analytical, analyzed on April 13, 2026 — found 99.669% purity on an 11.31 mg content. Of the four reports published in the catalogue, it is the lowest purity figure, which is exactly why it is the number worth citing when discussing MOTS-c, rather than the best lot's result. Anyone who wants to verify the figure can check the certificate of analysis directly.

Why they show up together in searches

KPV and MOTS-c do not share a mechanism, but they do turn up together in the same kind of search because both entered the research catalogue around the same time and both ship in the same format: a lyophilized powder vial. That generates the "what's the difference" question even though the accurate answer is, strictly speaking, "almost everything except the format."

The comparison makes sense for someone building a research catalogue who needs to decide which compound corresponds to which experimental line: inflammation (KPV) or mitochondrial metabolism (MOTS-c). It does not make sense as a "which one is better" comparison, because they do not investigate the same phenomenon.

Documentation and format for both

Both peptides ship as a lyophilized powder vial, with USP-grade diluents available separately. The material does not travel in a cold chain: lyophilized powder stays stable at room temperature for weeks, so the box carries no coolant and no gel pack. Cold only matters after reconstitution, when the solution is kept between 2 and 8 °C.

The entire PeptoClinic catalogue is quoted under the same standard: a minimum declared purity of 99% by HPLC, with batch documentation available for anyone who requests it at the time of inquiry.

The material is for research, not for human or veterinary use

Both KPV and MOTS-c are supplied strictly for research use (Research Use Only, RUO): in vitro and laboratory studies. Neither is a medicine, a supplement, or a food; neither is approved for human or veterinary consumption, diagnosis, or treatment; and none of their properties have been evaluated by ANMAT, the FDA, or any equivalent authority. No dosing, administration, or protocol guidance is offered, and any inquiry about use in people is answered by pointing back to this same limitation.